A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option | Zendy

Yao TianTian | Zendy; Qian JianDan | Zendy; Zhu WenYan | Zendy; Wang Yan | Zendy; Wang GuiQiang | Zendy

Premium

A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option

Author(s) -

Yao TianTian,

Qian JianDan,

Zhu WenYan,

Wang Yan,

Wang GuiQiang

Publication year - 2020

Publication title -

journal of medical virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.782

H-Index - 121

eISSN - 1096-9071

pISSN - 0146-6615

DOI - 10.1002/jmv.25729

Subject(s) - coronavirus , virology , covid-19 , lopinavir , medicine , severe acute respiratory syndrome coronavirus , betacoronavirus , middle east respiratory syndrome coronavirus , coronavirus infections , pandemic , disease , infectious disease (medical specialty) , outbreak , pathology

In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease‐19 (COVID‐19) from Wuhan caused a worldwide panic. There are no specific antiviral therapies for COVID‐19. However, there are agents that were used during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) epidemics. We could learn from SARS and MERS. Lopinavir (LPV) is an effective agent that inhibits the protease activity of coronavirus. In this review, we discuss the literature on the efficacy of LPV in vitro and in vivo, especially in patients with SARS and MERS, so that we might clarify the potential for the use of LPV in patients with COVID‐19.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research